One-year outcomes of panretinal photocoagulation in proliferative XXXX .

@entity1 @entity227 @entity6 @entity548 @entity1713
PURPOSE: To describe the clinical features and complications of @entity6 , @entity227 , and number of repeat treatments after panretinal photocoagulation for proliferative @entity6 in a tertiary care center. METHODS: A cohort study was conducted with data collection from medical records of @entity1 undergoing panretinal photocoagulation between 1985 and 1995 at the Scheie Eye Institute; 297 eyes of 186 @entity1 were eligible for study. RESULTS: The presence of neovascularization of the disk at baseline, an earlier onset of @entity6 , and a shorter duration of disease before panretinal photocoagulation were the strongest risk factors for needing an additional panretinal photocoagulation treatment. Sixty-two percent of eyes with poor @entity227 (< or =20/200) at baseline still had poor @entity227 at 1 year, and 76% with good @entity227 (> or =20/40) at baseline maintained good @entity227 at 1 year. Poor vision at baseline was the only risk factor for having poor vision at 1 year. @entity548 was present in 44% of eyes at baseline. New @entity548 developed in 37% of eyes during the first year after panretinal photocoagulation. A traction @entity1713 was present in 4% of eyes at baseline and newly developed in 6% of eyes during follow-up. A repeat panretinal photocoagulation treatment was performed in 39% of eyes after initial treatment. A vitrectomy was performed in 10% of eyes from baseline through the 1-year follow-up visit. CONCLUSIONS: The data from this study are useful for counseling @entity1 with respect to likely visual outcome, possibility of major complications from proliferative @entity6 , and the chance of undergoing additional laser treatment after panretinal photocoagulation.
